Fortier Charles, Durocher Yves, De Crescenzo Gregory
Life Sciences NRC Human Health Therapeutics Portfolio, Building Montréal-Royalmount, National Research Council Canada, Montréal, QC, H4P 2R2, Canada.
Nanomedicine (Lond). 2014 Jan;9(1):135-51. doi: 10.2217/nnm.13.194.
Biomedical nanotechnology has given a new lease of life to gene therapy with the ever-developing and ever-diversifying nonviral gene delivery nanocarriers. These are designed to pass a series of barriers in order to bring their nucleic acid cargo to the right subcellular location of particular cells. For a given application, each barrier has its dedicated strategy, which translates into a physicochemical, biological and temporal identity of the nanocarrier surface. Different strategies have thus been explored to implement adequate surface identities on nanocarriers over time for systemic delivery. In that context, this review will mainly focus on organic nanocarriers, for which these strategies will be described and discussed.
随着不断发展和日益多样化的非病毒基因递送纳米载体的出现,生物医学纳米技术为基因治疗带来了新的生机。这些纳米载体旨在跨越一系列屏障,以便将其携带的核酸运送到特定细胞的正确亚细胞位置。对于特定应用,每个屏障都有其专门的策略,这转化为纳米载体表面的物理化学、生物学和时间特性。因此,随着时间的推移,人们探索了不同的策略来在纳米载体上实现适当的表面特性以进行全身递送。在这种背景下,本综述将主要关注有机纳米载体,并将描述和讨论针对这些载体的策略。